High tumor-infiltrating lymphocytes (TILs) correlate with favorable prognosis in CRC, and programmed death ligand-1 (PD-L1)-targeted therapy may enhance sensitivity to conventional cancer therapy [17,18]. The gene discussed is CD274; the disease is cancer.